Short answer
AdaptHealth Corp. (AHCO) filed an 8-K current report with the SEC on July 20, 2026 reporting Item 1.01 (Entry into a Material Definitive Agreement), Item EX-99.1 (Exhibit EX-99.1). Sale of diabetes medical-device business to Cardinal Health subsidiary for $235.0 million cash, subject to working-capital adjustment.
AdaptHealth Corp. 8-K event analysis
AI summary of each reported item and its exhibits
Item 1.01 · Entry into a Material Definitive Agreement
- Sale of diabetes medical-device business to Cardinal Health subsidiary for $235.0 million cash, subject to working-capital adjustment
- $26.8 million escrowed at closing, comprising $8.0 million for purchase-price adjustments and $18.8 million for indemnification
- Proceeds monetize a substantial business segment, with financial impact dependent on transaction closing and treatment of divested operations
- Closing requires antitrust clearance and acceptance by at least 80% of offered employees plus a specified key employee
- Four-year North American non-compete limits AdaptHealth’s ability to re-enter the divested diabetes business; $9.4 million termination fee applies in certain antitrust failures
Item EX-99.1 · Exhibit EX-99.1
- Cardinal Health to acquire Diabetes Health for $235 million cash, subject to customary adjustments and regulatory approval
- Portfolio shift toward Sleep Health, Respiratory Health, and Wellness at Home businesses
- Proceeds targeted for core-business reinvestment and debt reduction, supporting balance-sheet deleveraging
- Diabetes Health classified as discontinued operations going forward, with financial and guidance updates due August 4, 2026
- Management expects improved go-forward revenue growth profile and adjusted EBITDA margins post-divestiture
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other AdaptHealth Corp. 8-K filings
Get the next AHCO 8-K as it lands
Follow AHCO for push alerts, or ask the research agent what this filing means.